foscarnet has been researched along with Seizures in 6 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 9.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 5.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Foscarnet was discontinued due to progressive renal insufficiency in all three patients (days 11, 19, and 21)." | 5.07 | A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. ( Koenig, S; Polis, MA; Seidel, EA, 1993) |
| "We report two cases of seizures and one case of hand cramping and finger paresthesia after starting foscarnet therapy with no evidence of predisposing risk factors, such as serum laboratory abnormalities, renal dysfunction, or known central nervous system (CNS) involvement." | 3.69 | Neurologic sequelae associated with foscarnet therapy. ( Liu, YQ; Lor, E, 1994) |
| "Penile ulcers are best managed by stopping the infusion until the ulcers heal; they may be prevented by paying careful attention to personal hygiene." | 2.40 | Minimising the dosage-limiting toxicities of foscarnet induction therapy. ( Jayaweera, DT, 1997) |
| "We present a patient with polymorphic ventricular tachycardia and subsequent ventricular fibrillation with acquired long QT syndrome secondary to herpes encephalitis." | 1.38 | Polymorphic ventricular tachycardia in a patient with herpes encephalitis. ( Blaschke, D; Boldt, LH; Haverkamp, W; Huemer, M; Parwani, A; Rolf, S; Wutzler, A, 2012) |
| "The potential for convulsions induced by the coadministration of ciprofloxacin (CPFX) and foscarnet (PFA) may be due not to a change in the distribution of CPFX to the brain but to a potential CPFX-induced inhibition of gamma-aminobutyric acid (GABA)-GABA(A) receptor binding in the presence of PFA." | 1.30 | Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice. ( Iga, T; Kawakami, JI; Matsuo, H; Nagata, A; Ryu, M; Sawada, Y; Uchida, T; Yamamoto, K, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huemer, M | 1 |
| Boldt, LH | 1 |
| Wutzler, A | 1 |
| Parwani, A | 1 |
| Rolf, S | 1 |
| Blaschke, D | 1 |
| Haverkamp, W | 1 |
| Lor, E | 1 |
| Liu, YQ | 1 |
| Seidel, EA | 1 |
| Koenig, S | 1 |
| Polis, MA | 1 |
| Jayaweera, DT | 1 |
| Matsuo, H | 1 |
| Ryu, M | 1 |
| Nagata, A | 1 |
| Uchida, T | 1 |
| Kawakami, JI | 1 |
| Yamamoto, K | 1 |
| Iga, T | 1 |
| Sawada, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
1 review available for foscarnet and Seizures
| Article | Year |
|---|---|
Minimising the dosage-limiting toxicities of foscarnet induction therapy.
Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Female; Fos | 1997 |
2 trials available for foscarnet and Seizures
| Article | Year |
|---|---|
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin | 1995 |
A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatinine; Dose-Response Relationship, Drug; Foscarnet; | 1993 |
3 other studies available for foscarnet and Seizures
| Article | Year |
|---|---|
Polymorphic ventricular tachycardia in a patient with herpes encephalitis.
Topics: Acute Disease; Acyclovir; Antiviral Agents; Defibrillators, Implantable; Electrocardiography; Enceph | 2012 |
Neurologic sequelae associated with foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Foscarnet; Hand; Humans; Infusions, Intravenous; Male; Mu | 1994 |
Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice.
Topics: Animals; Anti-Infective Agents; Antiviral Agents; Brain; Ciprofloxacin; Drug Interactions; Foscarnet | 1998 |